

ASTRAZENECA PLC
Form 6-K
November 04, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of November 2015

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82- _____

AstraZeneca PLC year-to-date and Q3 Results 2015

Tomorrow, Thursday, 5th November 2015, AstraZeneca PLC will release year-to-date and Q3 results for 2015 at 07:00 GMT.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

An analyst presentation of the year to date and Q3 results for 2015 will take place at 12:00 GMT and will be accessible by a choice of two routes:

Audio webcast

The presentation will be available to download on the AstraZeneca Investor Relations website <http://www.astrazeneca.com/investors> two hours before the analyst presentation begins.

Teleconference with Q&A. Dial in numbers:

UK (freephone): 0800 694 2370
International: +44 (0) 1452 557 749
Sweden (freephone): 0200 883 079
US (freephone): 866 977 7645

Conference ID: 75218823

Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca website <http://www.astrazeneca.com/investors>.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 04 November 2015

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary